eTheRNA will further explore the application of the TriMix technology as an in vivo product, implying a simple injection of the TriMix product itself instead of using cells as ‘vehicle’.
Initially, the TriMix technology was only applied as an ex vivo product. The ex vivo product consists of dendritic cells extracted from the patient’s body, which are then, in the laboratory, modified with TriMix in combination with the specific antigen mRNA. Successively, this cellular TriMix product is reinjected as an autologous product into the patient's body.
The ex vivo TriMix cellular product has been validated in mouse models, two phase I studies and two phase IIa studies in melanoma patients (more). Because commercialization of cellular products requires specific expertise as well as additional significant investments, eTheRNA intends to concentrate its proper efforts on the development of in vivo products, and to identify an experienced development partner to further advance this ex vivo product for selected patients with high unmet needs.
eTheRNA will concentrate its proper efforts on exploring the application of the TriMix technology as an in vivo product, implying a simple injection of the TriMix product itself without using cells as 'vehicle'.
A comprehensive preclinical in vivo data set supports this switch in the clinical development of the TriMix technology for an in vivo product. In vivo products are more convenient, as they do not require the extraction of cells from the body of individual patients, implying 'personalised medicine'. Instead, in vivo products can be produced in the lab and made available as an off-the-shelf, injectable product.
The proceeds of the EUR 24 million Series A financing will be primarily used for the development of this injectable product which will be studied in patients with advanced melanoma and triple negative breast cancer.